Amoxapine-associated agranulocytosis with thrombocytosis occurring early during recovery.
Agranulocytosis developed in a 35-year-old woman after she received 18 g of amoxapine, a tricyclic antidepressant, over 57 days. On the fifth day after cessation of amoxapine treatment, her platelet count rose from normal to a peak value of 999,000/mm3 on the 13th day. No cause for this thrombocytosis was apparent. Granulocytes appeared in the peripheral blood on the 15th day, and the thrombocytosis abated with the platelet count returning to a normal level by day 22. This confirms a previous report that amoxapine may be associated with agranulocytosis and suggests that thrombocytosis may occur as an early sign of recovery of the bone marrow in drug-associated toxic agranulocytosis.
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced* / Q000150:complications; D000657:Amoxapine / Q000009:adverse effects*; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects*; D055598:Chemical Phenomena; D002621:Chemistry; D003989:Dibenzoxazepines / Q000009:adverse effects*; D005260:Female; D006801:Humans; D013922:Thrombocytosis / Q000139:chemically induced* / Q000150:complications
D000929:Antidepressive Agents, Tricyclic; D003989:Dibenzoxazepines; D000657:Amoxapine